Description: Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from first-generation reversible tyrosine kinase inhibitors (TKI) to third-generation irreversible TKIs, of which osimertinib has been the widely accepted as first-line therapy. Despite survival improvement seen with osimertinib and its efficacy against acquired T790M mutation, resistance through on-target and off-target pathways eventually develop. This Element describes the structural biology and pathophysiology of EGFR-mutant NSCLC and discusses past, current, and future treatment options in the metastatic, neoadjuvant, and adjuvant settings. It describes the biology and recently approved treatment for EGFR-exon 20 insertion mutation and the treatment for the uncommon exon 18 (G719X), 20 (S768I), and 21 (L861Q) mutations. It also outlines the promising clinical applications of circulating tumor DNA (ctDNA).
Price: 15.48 GBP
Location: Hillsdale, NSW
End Time: 2025-01-23T04:41:23.000Z
Shipping Cost: 16.75 GBP
Product Images
Item Specifics
Return postage will be paid by: Buyer
Returns Accepted: Returns Accepted
After receiving the item, your buyer should cancel the purchase within: 60 days
Return policy details:
EAN: 9781009342308
UPC: 9781009342308
ISBN: 9781009342308
MPN: N/A
Format: Paperback, 75 pages
Author: So Yeon Kim
Item Height: 0.2 cm
Item Length: 22.9 cm
Item Weight: 0.07 kg
Item Width: 15.2 cm
Language: Eng
Publication Name: N/A
Publisher: Cambridge University Press
Type: N/A
